x
Breaking News
0

Celsion Corp (CLSN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Celsion's earnings

Delivery Method

Status

Add to/Remove from a Portfolio My Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
2.630 +0.210    +8.68%
19:59:59 GMT - Closed. Currency in USD ( Disclaimer )
After Hours
2.635
+0.005
+0.190%
20:06:27 GMT - Real-time Data
Type: Equity
Market: United States
ISIN: US15117N5032 
CUSIP: 15117N503
  • Volume: 3,074,314
  • Bid/Ask: 2.600 / 2.620
  • Day's Range: 2.350 - 3.090
Start Trading
Celsion 2.630 +0.210 +8.68%

CLSN Overview

 
Information about the Celsion Corp Stock. You can find more details by going to one of the sections under this page such as historical data, charts, technical analysis and others.
Loading
Last Update:
  • 1 Day
  • 1 Week
  • 1 Month
  • 3 Months
  • 6 Months
  • 1 Year
  • 5 years
  • Max
Prev. Close2.63
Day's Range2.35 - 3.09
Revenue480K
Open2.36
52 wk Range2.03 - 19.6
EPS - 10.21
Volume3,074,314
Market Cap9.85M
Dividend (Yield)0 (N/A)
Average Vol. (3m)586,047
P/E RatioN/A
Beta1.03
1-Year Change - 86.6%
Shares Outstanding4,070,173
Next Earnings DateN/A

Technical Summary

Type 5 mins 15 mins Hourly Daily Monthly
Moving Averages Buy Sell Buy Strong Sell Strong Sell
Technical Indicators Strong Buy Sell Strong Buy Strong Sell Strong Sell
Summary Strong Buy Sell Strong Buy Strong Sell Strong Sell

Candlestick Patterns

 

Filter Table By:

Candle Sticks Characteristics:

Time Frame
Type
Pattern Indication
Reliability
Pattern Timeframe Reliability Candles Ago Candle Time
Emerging Patterns
Three Outside Up 1D Current
Bullish doji Star 1M Current
Completed Patterns
Three Black Crows 1D 2 Jun 20, 2017
Doji Star Bearish 5H 3 Jun 21, 2017 02:00PM
Bullish Engulfing 30 4 Jun 22, 2017 01:30PM

Celsion Corp News & Analysis

Celsion Corp Quotes

Exchange Last Bid Ask Volume Change % Currency Time
  NASDAQ 2.630 2.600 2.620 3,074,314 +8.68% USD 19:59:59  
  Stuttgart 2.497 0.000 0.000 0 +20.80% EUR 19:26:00  
  Berlin 2.104 2.116 2.264 0 +5.31% EUR 06:08:00  
  Tel Aviv 850.4 848.0 857.0 44,275 +7.56% ILS 14:24:00  

Trending Stocks

Create Alert
Add to Portfolio
Add to/Remove from a Portfolio  
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

  Name Last High Low Chg. Chg. % Vol. Time
  AMD 14.371 14.500 13.560 +0.391 +2.80% 148.05M 19:59:59  
  Apple 145.63 146.70 145.12 -0.24 -0.16% 18.68M 19:59:59  
  Tesla 382.61 385.00 373.57 +6.21 +1.65% 7.49M 19:59:59  
  Bed Bath&Beyond 33.74 34.10 33.40 +0.08 +0.24% 4.69M 19:59:59  
  Amazon.com 1,001.30 1,006.96 997.20 -0.93 -0.09% 2.22M 19:59:59  
  Delcath 0.2362 0.2650 0.1850 -0.0300 -11.27% 193.86M 19:59:59  
  BlackBerry 11.06 11.14 10.46 +0.41 +3.85% 17.17M 19:59:59  
  NVIDIA 158.37 160.34 157.40 -1.10 -0.69% 11.69M 19:59:59  
  Oracle 50.30 51.85 50.16 +3.97 +8.57% 62.56M 19:59:59  
  Facebook 153.40 154.55 152.91 -0.51 -0.33% 12.80M 19:59:59  

Celsion Corp Company Profile

IndustryBiotechnology & Drugs
SectorHealthcare
Employees

19

Equity Type

ORD

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

Read More

Start Trading With Top Industry Brokers

Brokers Regulation Minimum Deposit
U.S. Commodity Futures Trading Commission (United States) $250 Start Trading
Securities and Exchange Commission (United States) Start Trading

My Sentiments

Add your sentiment:
or
 
Members' Sentiments:
Bullish
67%
Bearish
33%

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

 
Are you sure you want to delete this chart?
 
 
Replace the attached chart with a new chart ?
Post
Post also to:
1000
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.

Latest CLSN Comments

syed rafay 2
syed rafay 2 Sep 03, 2013 11:41PM GMT
Saved. See Saved Items.
This comment has already been saved in your Saved Items
first target reached 1.15
syed rafay 2
syed rafay 2 Aug 20, 2013 9:17PM GMT
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Buy between 1.05 - 1.15 targets 1.25 - 1.45 - 1.75 - 1.95 stop loss .080
syed rafay 2
syed rafay 2 Jun 17, 2013 7:14PM GMT
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$CLSN almost reached 1.10 today low is 1.13
Show more comments
 
Are you sure you want to delete this chart?
 
 
Replace the attached chart with a new chart ?
Post 1000
Please wait a minute before you try to comment again.
 
 
 
Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Add Chart to Comment
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.